Lotrel (Amlodipine/Benazepril) – Evidence‑Based Hypertension Management

Indications and Initial Dosing

Lotrel should not be used as first‑line monotherapy for hypertension; it is reserved for patients who need dual therapy after an inadequate response to a single agent, typically initiated at 2.5 mg/10 mg or 5 mg/10 mg once daily with titration based on blood‑pressure response. American Heart Association (AHA) recommendation. 1, 2
In stage 1 hypertension (clinic BP ≈ 130‑139/80‑89 mmHg), initiate therapy with a thiazide‑type diuretic rather than Lotrel. AHA guidance. 1
For stage 2 hypertension (clinic BP ≥ 160/100 mmHg or >20/10 mmHg above target), dual therapy is appropriate from the outset; Lotrel is a suitable option. AHA guidance. 1, 2

After starting Lotrel, wait 2–4 weeks before any dose adjustment to allow the full antihypertensive effect to manifest. AHA recommendation. 1, 3
Blood‑pressure control should be achieved within 3 months of initiation; if targets are not met, add a third antihypertensive agent rather than exceeding the maximum Lotrel dose. American College of Cardiology (ACC) recommendation. 4, 3

Target BP < 130/80 mmHg for adults with confirmed hypertension who have a 10‑year ASCVD risk ≥ 10 % or known cardiovascular disease. ACC guideline. 4, 3
A target of < 130/80 mmHg may also be reasonable for adults without additional cardiovascular risk markers. AHA guidance. 3
The optimal diastolic range is 70–79 mmHg; treatment should not be withheld solely because diastolic pressure falls below 70 mmHg while systolic pressure remains elevated. ACC recommendation. 4
In chronic kidney disease, aim for 130‑140/70‑79 mmHg to balance cardiovascular benefit with the risk of acute kidney injury. ACC recommendation. 4
For elderly patients (65‑85 years), a systolic target < 130 mmHg is acceptable if tolerated and confirmed by ambulatory monitoring. ACC recommendation. 4

Absolute contraindication: history of angioedema with any ACE‑inhibitor. AHA statement. 1
Absolute contraindication: pregnancy or planned pregnancy; ACE‑inhibitors cause fetal toxicity. ACC statement. 4
Absolute contraindication: concurrent use of aliskiren in patients with diabetes or chronic kidney disease. AHA statement. 1
Relative contraindication: concurrent use of another ACE‑inhibitor or ARB; dual RAAS blockade increases adverse events without added benefit. ACC and AHA statements. 4, 1

Initial monitoring: measure clinic blood pressure monthly until the target is reached, then every 3–6 months. AHA recommendation. 3
Long‑term monitoring: reassess overall cardiovascular risk factors (lipids, glucose) every 2 years. ACC recommendation. 4

If BP remains > 130/80 mmHg on the maximum tolerated Lotrel dose (typically 10 mg/40 mg) after 3 months, add a third antihypertensive agent (e.g., thiazide‑type diuretic). ACC recommendation. 4

Do not use Lotrel as first‑line monotherapy in stage 1 hypertension; thiazide diuretics have superior outcome data. AHA and American Society of Nephrology (ASN) evidence. 1, 2, 5
Avoid combining Lotrel with another ACE‑inhibitor or ARB; dual RAAS blockade increases harm without benefit. ACC and AHA statements. 4, 1
Do not continue Lotrel during pregnancy because ACE‑inhibitors cause fetal renal dysgenesis and death. ACC statement. 4

The American College of Cardiology recommends starting with a single first-line agent, preferably a thiazide diuretic, for stage 1 hypertension, and initiating therapy with two first-line agents simultaneously for stage 2 hypertension 6, 7
The stepped-care approach, which involves starting with a single agent and sequentially adding more agents, is a reasonable approach for most patients, as recommended by the American College of Cardiology 7, 8

The American Heart Association recommends thiazide or thiazide-like diuretics as the preferred first-line agent for hypertension treatment, with chlorthalidone 12.5-25 mg daily or hydrochlorothiazide 12.5-25 mg daily being suitable options 6, 9

The American College of Cardiology suggests adding a second agent from a different class rather than maximizing the first drug's dose if blood pressure remains uncontrolled after 2-4 weeks of initial therapy 10
For non-Black patients without compelling indications, adding an ACE inhibitor or ARB is recommended, while for Black patients, a calcium channel blocker is preferred 6, 9, 10

The American Geriatrics Society recommends starting with lower doses and titrating more gradually in older adults, and monitoring closely for orthostatic hypotension, especially when using two-drug initial therapy 6, 7
The American Diabetes Association recommends using ACE inhibitors or ARBs to provide additional renal protection in patients with diabetes 10